Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

60760258

A replay of the webcast will be available through May 17, 2007 and may be accessed by dialing 1-888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 25344900. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.

Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusett
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:4/24/2015)... 2015  Novartis Pharmaceuticals Corporation (NPC) has been named the ... row on the annual DiversityInc Top 50 Companies for Diversity ... Companies for Diversity on April 23 at an awards ceremony ... ranked second on the DiversityInc Top 10 Companies for Recruitment ... Resource Groups list. David Epstein , ...
(Date:4/24/2015)... , April 24, 2015 Hospira, Inc. ... the development of biosimilar therapies, spoke about the importance ... the European Generics Association (EGA) annual European Biosimilars Group ... The company also announced the publication of a pivotal ... achieving the full promise of biosimilars." ...
(Date:4/23/2015)... (NYSE: RMD ) today announced results for its ... was $422.5 million, a 6 percent increase compared to ... increase on a constant currency basis).  Net income was ... the quarter ended March 31, 2014.  Diluted earnings per ... 2 percent compared to the quarter ended March 31, ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
... Dec. 20, 2010 Ambit Biosciences (Ambit), ... trials for two products AC430, a selective Janus Kinase ... The Phase I trial for AC430 is a ... trial in healthy volunteers.  AC430 will be administered orally ...
... Center for Business Intelligence (CBI) has been recognized as a ... was awarded recently to Kathleen Y. Coffey, CBI President, by ... Boston Park Plaza Hotel.   The Top ... $47.5B in annual revenue and $202,664 employees. Over 500 women ...
Cached Medicine Technology:Ambit Biosciences Initiates Two Phase I Clinical Trials 2The Center for Business Intelligence (CBI) Receives Top 100 Women-Led Businesses Award 2
(Date:4/24/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... auto insurance for senior citizens . , Senior ... does not mean that they cannot find affordable coverage. ... can find the right coverage for their cars at ... like http://lowcostcarinsuranceprice.com/ provides free leads from various ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two ... and cognition. , A unique combination of herbs ... Wellness Flavonoid Complex apart from other antioxidant supplements. ... to support antioxidation versus the use of single ... tea extract, Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 ...
(Date:4/24/2015)... With years of experience providing ... proud to be partnered with a veterinary college where ... year. This partnership has brought new payment options for ... After providing an in-house payment plan for many years, ... wanted to increase financing options available to avoid having ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 IntelliSoft ... provider enrollment and contract management software, featured IntelliCred ... Medical Staff Services Annual Educational Conference (IAMSS) ... Resort in Oak Brook, Illinois. , Notable improvements ... , Contract Linking: A ...
(Date:4/24/2015)... Telematics Berlin is the foremost Automotive Data event ... suppliers, content providers, associations and government bodies. From industry ... see them converge in Berlin. This year’s start-up competition ... companies currently at the forefront of Europe’s Silicon Valley ... centric products, ParkTAG are one of the first social ...
Breaking Medicine News(10 mins):Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:IntelliSoft Group Version 14.2 of IntelliCred featured at the Illinois Association of Medical Staff Services Annual Educational Conference 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3
... American Heart Association extend their sympathy to the family and friends ... , "It,s a shame when someone his age dies so ... "Although we don,t know all the details of the situation, ... react quickly. Our thoughts and prayers are with the Jackson ...
... Wash., June 25 Verathon Inc., maker of ... announced today the appointment of Kendall Stever as ... will include management and oversight of the Company,s ... functions for company headquarters in Washington State, taxation, ...
... finds , THURSDAY, June 25 (HealthDay News) -- Consumption of ... associated with it. Worldwide, one in 25 deaths and 5 ... are related to alcohol, according to a new study. , ... of about 1.6 gallons (6.2 liters) of pure ethanol a ...
... ... Cases, , ... CO (PRWEB) June 25, 2009 -- Two grocery checkers--a 28-year-old female triathlete and a ... are identical. Which employee will return to work sooner? Is there anything you can ...
... In a 6-5 decision in Richmond Medical Center v. ... ban on partial birth infanticide -- a law that mirrors the ... United for Life (AUL) provided litigation support to the ... Virginia,s law. In addition, AUL Senior Counsel Clarke Forsythe assisted ...
... there is no cure for HIV/AIDS. However, major advances ... with HIV/AIDS. For example, Dr. Michael Hall has revolutionized ... diseases. He envisions a synergy between the evolution of ... the Hall Longevity Clinic Lifecard , ...
Cached Medicine News:Health News:American Heart Association Extends Sympathy to Family of Singer Michael Jackson 2Health News:Verathon Inc. Appoints Kendall Stever as Chief Financial Officer 2Health News:Alcohol-Related Ills Increasing Worldwide 2Health News:Alcohol-Related Ills Increasing Worldwide 3Health News:MDGuidelines Offers New Predictive Modeling Feature 2Health News:MDGuidelines Offers New Predictive Modeling Feature 3Health News:MDGuidelines Offers New Predictive Modeling Feature 4Health News:Americans United for Life Applauds Fourth Circuit Protecting Women and Children by Upholding Virginia Partial Birth Abortion Statute 2Health News:Dr. Hall Revolutionizes National HIV Testing Day 2
... Varicella-Zoster Virus (VZV) IgG Enzyme-Linked Immunosorbent ... and quantitative determination of IgG antibody to ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
... Inc. Mumps IgG ELISA test system is ... IgG antibody in human serum. When performed ... this test, together with other clinical information, ... status, and/or aid in the diagnosis of ...
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
Medicine Products: